\n<\/p>\n
23andMe, the corporate whose mail-in self-testing kits grew to become synonymous with DNA testing<\/a>, is submitting for chapter<\/a> amid slowing gross sales 4 years after it went public. Anne Wojcicki<\/a>, who co-founded 23andMe in 2006, is stepping down as CEO as the corporate tries to discover a purchaser<\/a>.<\/p>\n In January,\u00a023andMe stated<\/a> it was exploring choices for a sale amid slowing demand for its product and the fallout of a significant knowledge breach in 2023. In 2024, the corporate agreed to a monetary settlement for the breach, which affected 6.9 million customers. The corporate had additionally introduced layoffs of about 40% of its workforce in late 2024<\/a>. Lately, the corporate’s inventory dipped under a greenback<\/a>, placing it at risk of being delisted from the NASDAQ.\u00a0<\/p>\n In a observe to clients<\/a>, the corporate stated nothing is at present altering about the way in which it shops, manages or protects buyer knowledge and that the corporate remains to be open for enterprise and promoting DNA kits. “By this course of, we’ll search to discover a associate who shares our dedication to buyer knowledge privateness and permits our mission of serving to folks entry, perceive and profit from the human genome to dwell on,” the corporate stated in its put up.<\/p>\n At its peak, 23andMe grew to become the best-known identify within the rising space of DNA self-testing, with customers paying $99 for kits that gave them insights into their genetic make-up, potential kinfolk and ancestry. However the firm’s momentum slowed down in recent times after its $3.5 billion public providing in 2021.<\/p>\n Individuals who have used 23andMe and are involved about what would possibly occur to their knowledge in a sale have choices: They’ll obtain their info then delete their account<\/a>, in addition to ask the corporate to discard their DNA materials along with deleting the information. Doing so will preserve DNA info from being utilized in future analysis, however it may’t be faraway from analysis that has already been accomplished.<\/p>\n Arthur Caplan<\/a>, head of the division of medical ethics<\/a> at NYU’s Grossman Faculty of Drugs, has been vital of 23andMe for many years. He stated he was not shocked by the announcement, having simply predicted it in January<\/a>.<\/p>\n “They had been extra eager about getting knowledge, saliva, to resell,” Caplan advised CNET. “It was marketed and obtained as a cute hobbyist type of factor. However that wasn’t actually the purpose that gave it the billions of {dollars} of worth it as soon as had.”\u00a0<\/p>\n Caplan stated the corporate’s enterprise mannequin promised ancestry info that he believes was not dependable to start with.\u00a0<\/p>\n “I do not assume the science was excellent,” he stated, including with a sale of the corporate, there is no authorized obligation to make sure buyer privateness below one other proprietor.\u00a0<\/p>\n The dangers, Caplan stated, is that the information might be utilized in methods individuals who’ve handed over their saliva cannot anticipate.\u00a0<\/p>\n “DNA info may be very delicate — it may let you know issues about paternity, it may lead authorities businesses to come back after you that you just did not take into consideration,” he stated. “The genetic knowledge might be used to promote or market to you. A 3rd celebration may resolve you are not eligible for insurance coverage.<\/p>\n “My recommendation is get your knowledge out of there. I might not depart it there and it is likely to be too late,” Caplan stated.<\/p>\n<\/div>\n‘Get your knowledge out of there’<\/h2>\n